Liminal BioSciences (LMNL) Reports Q3 Revenues of $600K

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Liminal BioSciences (LMNL) Reports Q3 Revenues of $600K

Liminal BioSciences Reports Third Quarter Financial Results

November 12, 2020 4:57 PM EST

PDUFA Target Action Date of June 5, 2021 for Ryplazim® (plasminogen) BLA Submission Ryplazim® (plasminogen) Abstracts Selected for Presentation at American Society of Hematology (ASH) in early December Changes to Board of Directors OXER1 Antagonist Preclinical R&D Program Acquired New Appointments to Board of Directors US$30 MM in gross proceeds from a private placement closed in November C$29.1 MM in proceeds from long-term loan from SALP in September Executive team changes

LAVAL, QC, and CAMBRIDGE, England, Nov. 12, 2020 /PRNewswire/ -... More